ARVINAS, INC.
ARVNNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $262.6M | $263.4M | $78.5M | $131.4M | $46.7M | $21.8M |
| Operating income | −$118.5M | −$250.2M | −$401.5M | −$263.2M | −$188.4M | −$120.8M |
| Net income | −$80.8M | −$198.9M | −$367.3M | −$282.5M | −$191.0M | −$119.3M |
| Total assets | $717.9M | $1.09B | $1.30B | $1.27B | $1.58B | $717.4M |
| Total liabilities | $284.0M | $529.7M | $644.6M | $703.9M | $799.9M | $75.2M |
| Equity | $433.9M | $561.7M | $660.0M | $564.9M | $781.7M | $642.2M |
| EPS (diluted) | $-1.14 | $-2.77 | $-6.62 | $-5.31 | $-3.82 | $-3.02 |
| Shares out. | 68.8M | 68.1M | 53.3M | 53.0M | 48.9M | 39.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −45.1%
- Net margin
- −30.8%
- Return on equity
- −18.6%
- Return on assets
- −11.3%
- Return on capital (ROCE)
- −20.6%
- Liabilities / assets
- 39.6%
- Debt / equity
- 0.65×
- Book value / share
- $6.31
- Revenue growth (YoY)
- −0.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -1.73distress
- Accruals / assets
- 26.9%high accruals
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 5 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Recruitingreadout ~2027-11-30A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
- Phase 1Recruitingreadout ~2028-03A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Portfolio Management LlcPassive (13G)Apr 28, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- D. E. Shaw & Co, L.P.Passive (13G)Nov 14, 2025
- Citadel Advisors LlcPassive (13G)Nov 14, 2025
- Logos Global Management LpActivist (13D)Oct 15, 2025
- Price T Rowe Associates Inc /Md/Passive (13G)Aug 14, 2025
- Ecor1 Capital, LlcPassive (13G)May 15, 2025
- Blackrock, Inc.Passive (13G)Apr 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Teel RandyOfficer — President and CEO | May 21, 2026 | Sell | 2,209 | $9.04 |
| Saik AndrewOfficer — Chief Financial Officer | May 11, 2026 | Sell | 11,139 | $9.94 |
| Loomis David KOfficer — VP, Chief Accounting Officer | May 11, 2026 | Sell | 1,919 | $9.94 |
| Cacace Angela MOfficer — Chief Scientific Officer | May 11, 2026 | Sell | 9,657 | $9.94 |
| Berkowitz NoahOfficer — Chief Medical Officer | May 11, 2026 | Sell | 11,108 | $9.94 |
| Teel RandyOfficer — President and CEO | May 11, 2026 | Sell | 9,657 | $9.94 |
| Berkowitz NoahOfficer — Chief Medical Officer | Mar 18, 2026 | Sell | 6,435 | $11.10 |
| Morrison BriggsDirector | Mar 6, 2026 | Buy | 20,000 | $13.40 |
| Loomis David KOfficer — VP, Chief Accounting Officer | Feb 26, 2026 | Grant | 12,420 | $0.00 |
| Cacace Angela MOfficer — Chief Scientific Officer | Feb 26, 2026 | Grant | 45,000 | $0.00 |
| Berkowitz NoahOfficer — Chief Medical Officer | Feb 26, 2026 | Grant | 45,000 | $0.00 |
| Saik AndrewOfficer — Chief Financial Officer | Feb 26, 2026 | Grant | 45,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 5.0M | 4.4 | +14.0% |
| Apr 30, 2026 | 4.4M | 7.3 | +0.7% |
| Apr 15, 2026 | 4.4M | 4.9 | -2.6% |
| Mar 31, 2026 | 4.5M | 4.6 | -5.8% |
| Mar 13, 2026 | 4.8M | 6.7 | +11.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 12, 2026
- Entered a material agreement · Regulation FD disclosureMay 12, 2026
- Regulation FD disclosure · Other material eventMay 1, 2026
- Regulation FD disclosure · Other material eventMar 18, 2026
- Results of operationsFeb 24, 2026
- Director / officer changeFeb 12, 2026
- Regulation FD disclosure · Other material eventDec 8, 2025
- Results of operationsNov 5, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.